While this paper did not identify the signals from LMP2A that are required to reach this effect, subsequent studies using this same mouse model of Burkitt’s lymphoma demonstrated that the mTOR inhibitor, rapamycin, blocks the LMP2A-mediated enhancement in tumor development [58]. The gene discussed is MTOR; the disease is Burkitt lymphoma.